NASDAQ$CSTL

Castle Biosciences Inc · Q1 2018 earnings

Q1 2018 earnings · · Investor relations

Headline financials

Total Revenue

$3.66M

No prior period
EPS (adj)

-$2.89

No prior period
Net Income

-$3.63M

No prior period
Gross Profit

$2.41M

No prior period

Revenue & EPS history

Castle Biosciences · Revenue · Quarterly

$3.66M

Q1 2018
Beat estimate in 4 of 10 quarters(40%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2018

Historical avgQ1 2018

+0.1%

Avg return

Earnings day

-2.1%

Avg return

5 days after

+0.7%

Avg return

30 days after

41%

13 / 32 earnings

Positive

+21.8%

Q3 2025

Best reaction

-28.0%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.6%-22.6%-14.4%
Q4 2025-7.3%-11.6%-26.2%
Q3 2025+21.8%+27.1%+52.4%
Q1 2025-11.7%-10.5%-9.2%
Q4 2024-14.2%-15.7%-21.1%
Q3 2024-6.0%+0.4%-3.8%
Q2 2024+11.8%+20.4%+29.8%
Q1 2024+10.5%+8.1%+5.6%
Q4 2023-28.0%-15.4%-11.7%
Q3 2023+14.5%+14.6%+27.2%
Q2 2023+12.3%+7.0%+17.6%
Q1 2023-0.2%+2.6%+3.0%
Q4 2022-7.7%-0.3%-10.2%
Q3 2022-6.0%-23.7%-0.4%
Q2 2022+0.3%+11.1%-12.6%
Q1 2022-4.1%-6.8%+3.1%
Q4 2021+4.5%-5.4%-1.5%
Q3 2021-7.2%-13.2%-23.2%
Q2 2021-4.9%-10.3%+6.5%
Q1 2021-9.5%-8.5%+17.5%
Q4 2020-9.9%-6.9%+2.3%
Q3 2020-3.3%-2.6%+12.3%
Q2 2020+0.1%-1.1%+19.8%
Q1 2020+17.1%+18.9%+22.4%
Q1 2019+17.1%+18.9%+22.4%
Q1 2018-1.5%-18.2%-4.7%
Q4 2019-1.5%-18.2%-4.7%
Q3 2018+20.0%-7.0%-6.1%
Q3 2019+18.2%+30.3%+32.9%
Q2 2018-6.9%-9.0%-33.8%
Q2 2019-6.9%-9.0%-33.8%
Q4 2018-6.9%-9.0%-33.8%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro